ArticleCancer research2010
Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model.iScience · 2023Article
- Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis.Biomedicines · 2022Article
- Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas .Vaccines · 2020Article
- An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.Cancer immunology, immunotherapy : CII · 2019Article
- Novel EXO-T vaccine using polyclonal CD4OncoTargets and therapy · 2018Review
- Article
- Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2Oncoimmunology · 2016Article
- Review
- Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.Cancer immunology research · 2015Article
- Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.Cancer immunology research · 2015Article
- The Promise of Preventive Cancer Vaccines.Vaccines · 2015Review
- Article
- Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.PloS one · 2015Article
- Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.Cancer research · 2014Article
- Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Breast cancer research : BCR · 2014Article
- "Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.Frontiers in oncology · 2014Article
- Preclinical HER-2 Vaccines: From Rodent to Human HER-2.Frontiers in oncology · 2013Article
- Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers.Frontiers in oncology · 2013Article
- Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).PloS one · 2013Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Immune tolerance to tumor-associated self-antigens poses a major challenge in the ability to mount an effective cancer vaccine response. To overcome immune tolerance to HER-2, we formulated DNA vaccines that express both human HER-2 and heterologous rat Neu sequences in separate plasmids or as single hybrid constructs that encode HER-2/Neu fusion proteins. Candidate vaccines were tested in Her-2 transgenic (Tg) mice of BALB/c (BALB), BALB/cxC57BL/6 F1 (F1), or C57BL/6 (B6) background, which exhibit decreasing immune responsiveness to HER-2. Analysis of various cocktails or hybrid vaccines defined a requirement for particular combination of HER/2/Neu sequences to effectively prime immune effector cells in HER-2 Tg mice. In B6 HER-2 Tg mice, rejection of HER-2-positive tumors protected mice from HER-2-negative tumors, providing evidence of epitope spreading. Our findings show that a strategy of combining heterologous antigen with self-antigens could produce a potent DNA vaccine that may be applicable to other tumor-associated antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.